CMND Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.669

Open

0.628

VWAP

0.65

Vol

41.49K

Mkt Cap

1.38M

Low

0.623

Amount

27.00K

EV/EBITDA(TTM)

--

Total Shares

2.09M

EV

-9.36M

EV/OCF(TTM)

--

P/S(TTM)

--

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

Show More

Events Timeline

(ET)

2026-03-19

09:00:00

Clearmind Medicine Advances CMND-100 Clinical Trial

2026-03-17 (ET)

2026-03-17

09:20:00

Clearmind Medicine Announces Six Patents in Hong Kong

2026-03-12 (ET)

2026-03-12

08:00:00

SciSparc's NeuroThera Labs Advances Collaboration with Clearmind on Patent Publication

2026-03-11 (ET)

2026-03-11

09:10:00

Clearmind Medicine Continues Enrollment for Third Cohort in Clinical Trial

2026-03-04 (ET)

2026-03-04

07:50:00

Clearmind Medicine Clinical Trial Approved to Continue

News

Yahoo Finance

03-10Yahoo Finance

Clearmind Unveils Patent for Innovative Weight Loss Therapy

Newsfilter

03-04Newsfilter

Clearmind's CMND-100 Clinical Trial Receives Approval

PRnewswire

02-19PRnewswire

Clearmind's MEAI Drug Breakthrough in Obesity Treatment

Newsfilter

02-19Newsfilter

Clearmind's MEAI Drug Breakthrough in Obesity Treatment

NASDAQ.COM

02-09NASDAQ.COM

Clearmind Medicine Reports Positive Clinical Trial Results

Newsfilter

02-09Newsfilter

Clearmind Reports Positive Safety Results for AUD Drug in Phase I/IIa Trial

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Clearmind Medicine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Low float stock screener

Intellectia · 1484 candidates

List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

Lion Group Holding Ltd

638.91K

La Rosa Holdings

711.55K

Erayak Power Solution Group Inc

831.04K

NewGenIvf Group Ltd

864.77K

Quhuo Ltd

948.08K

Biodexa Pharmaceuticals PLC

1.01M

Find stocks with low float

Intellectia · 2888 candidates

Region: USShares Outstanding: <= 150,000,000

Ticker

Name

Market Cap$

Aditxt Inc

2.59M

Greenwave Technology Solutions Inc

4.33M

Golden Heaven Group Holdings Ltd

5.19M

American Rebel Holdings Inc

3.47M

iPower Inc

5.62M

UTime Ltd

1.44M

Whales Holding CMND

Trading Trends

People Also Watch

Frequently Asked Questions

What is Clearmind Medicine Inc (CMND) stock price today?

The current price of CMND is 0.66 USD — it has increased 0.76

What is Clearmind Medicine Inc (CMND)'s business?

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

What is the price predicton of CMND Stock?

Wall Street analysts forecast CMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clearmind Medicine Inc (CMND)'s revenue for the last quarter?

Clearmind Medicine Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

What is Clearmind Medicine Inc (CMND)'s earnings per share (EPS) for the last quarter?

Clearmind Medicine Inc. EPS for the last quarter amounts to USD, decreased -100.00

How many employees does Clearmind Medicine Inc (CMND). have?

Clearmind Medicine Inc (CMND) has 4 emplpoyees as of March 22 2026.

What is Clearmind Medicine Inc (CMND) market cap?

Today CMND has the market capitalization of 1.38M USD.